Evidence map›Paper›PMID 34201045›Full record

ArticleJournal of personalized medicine2021

Accuracy of a Machine-Learning Algorithm for Detecting and Classifying Choroidal Neovascularization on Spectral-Domain Optical Coherence Tomography.

Andreas Maunz, Fethallah Benmansour, Yvonna Li, Thomas Albrecht, Yan-Ping Zhang, Filippo Arcadu, Yalin Zheng, Savita Madhusudhan, Jayashree Sahni

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00891735 phase3completednot on this map

A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration

TypeinterventionalSponsorGenentech, Inc.Ran2009 to 2012Enrolled1,097ConditionsAge-related Macular DegenerationArmsRanibizumab
NCT02484690 phase2completednot on this map

A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

TypeinterventionalSponsorHoffmann-La RocheRan2015 to 2017Enrolled273ConditionsChoroidal NeovascularizationArmsFaricimab, Ranibizumab, Sham Procedure
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Age-Related Macular Degeneration and Diabetic Retinopathy.Journal of personalized medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Andreas MaunzPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.ORCID 0000-0002-2784-9456
Fethallah BenmansourPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Yvonna LiPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Thomas AlbrechtPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Yan-Ping ZhangPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Filippo ArcaduPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Yalin ZhengDepartment of Eye and Vision Science, University of Liverpool, Liverpool L7 8XP, UK.ORCID 0000-0002-7873-0922
Savita MadhusudhanDepartment of Eye and Vision Science, University of Liverpool, Liverpool L7 8XP, UK.
Jayashree SahniPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Roche (Switzerland) · CHUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the performance of a machine-learning (ML) algorithm to detect and classify choroidal neovascularization (CNV), secondary to age-related macular degeneration (AMD) on spectral-domain optical coherence tomography (SD-OCT) images.

methodsBaseline fluorescein angiography (FA) and SD-OCT images from 1037 treatment-naive study eyes and 531 fellow eyes, without advanced AMD from the phase 3 HARBOR trial (NCT00891735), were used to develop, train, and cross-validate an ML pipeline combining deep-learning-based segmentation of SD-OCT B-scans and CNV classification, based on features derived from the segmentations, in a five-fold setting. FA classification of the CNV phenotypes from HARBOR was used for generating the ground truth for model development. SD-OCT scans from the phase 2 AVENUE trial (NCT02484690) were used to externally validate the ML model.

resultsThe ML algorithm discriminated CNV absence from CNV presence, with a very high accuracy (area under the receiver operating characteristic [AUROC] = 0.99), and classified occult versus predominantly classic CNV types, per FA assessment, with a high accuracy (AUROC = 0.91) on HARBOR SD-OCT images. Minimally classic CNV was discriminated with significantly lower performance. Occult and predominantly classic CNV types could be discriminated with AUROC = 0.88 on baseline SD-OCT images of 165 study eyes, with CNV from AVENUE.

conclusionsOur ML model was able to detect CNV presence and CNV subtypes on SD-OCT images with high accuracy in patients with neovascular AMD.

Indexed as

age-related macular degenerationchoroidal neovascularizationclassificationmachine learningoptical coherence tomography

Identifiers

PMID34201045
PMCPMC8227725
OpenAlexW3169295182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.